JAZZ FDA approves Ziihera® in first-line HER2+ advanced GE adenocarcinoma
Jazz Pharmaceuticals says the U.S. FDA approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.